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We read with interest the correspondence by Palamar et al. [1]
regarding our previously published study. We are grateful for the
proposed discussion. The authors raise interesting challenges with
regard to our daily practice. We would like to comment on the
points mentioned.
Piriformis muscle syndrome (PMS) is probably an under-
estimated entity [2]. The main difﬁculty in establishing diagnosis
is the lack of a gold standard. We aimed to develop a clinical score to
select patients and then propose oriented therapeutic management.
In many publications [3–8], this speciﬁc oriented management
consists in performing a therapeutic test to conﬁrm the diagnosis.
By deﬁnition, this probable entrapment neuropathy associates
a classical range of symptoms corresponding to truncal sciatica
with frequently ﬂuctuating pain, initially in the muscles of the
buttocks. In our work [9,10], to respect this deﬁnition, we favoured
the existence of distal ﬂuctuating and positional symptoms. In this
context, the nosology of PMS should be clariﬁed to include buttock
pain associated with irradiation in the territory of the posterior
thigh nerve. These clinical symptoms prompted us to consider
compression at the infra-piriformis foramen. Therefore, PMS must
be distinguished from isolated buttock pain, in which the
piriformis muscle can sometimes be incriminated, but the
pathophysiologic features differ. Furthermore, many spinal or
hip pathologies can cause pain around the piriformis muscle.
In this context, a diagnostic test with anesthetics delivered to
the piriformis muscle is of interest to identify the muscle
responsible for the buttock pain [6–8]. However, this test does
not allow for evaluating the sciatica, for which the main differentialDOIs of original articles: http://dx.doi.org/10.1016/j.rehab.2013.04.003, http://
dx.doi.org/10.1016/j.rehab.2015.01.005
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1877-0657/ 2015 Elsevier Masson SAS. All rights reserved.diagnosis remains its disco-radicular origin. An anesthetic test at
the infrapiriform foramen does not allow for identifying the
precise origin of the nerve root compression or the sciatic nerve
itself.
Topographic features are important for identifying the pir-
iformis muscle. Inserted proximally on the ventral side of the
sacrum, the ﬁbers travel into the gluteal area and pass into the
large sciatic notch to ﬁt into the posterior part of the greater
trochanter. Thus, for clinical identiﬁcation, the patient is placed in
the lateral decubitus position on the side contralateral to pain. The
knee is placed with the painful side down and ﬂat on the table, with
the foot hooked behind the contralateral leg. We then draw a
triangle whose base comprises the line joining the posterior
superior iliac spine (PSIS) and the top of the inter-gluteal fold. The
apex of this triangle is represented by the posterior edge of the
greater trochanter. The piriformis muscle is projected on the line
joining the middle of the PSIS segment–the top of the inter-gluteal
fold to the greater trochanter. We usually inject botulinum toxin
into a proximal site and a distal site. Electromyography is used to
detect ‘‘spontaneous’’ electrical activity of this muscle and activity,
by asking the patient to perform an active lateral rotation (lifting
the knee off the exam table) [11–13]. In recent years, we have
coupled this electrical identiﬁcation with ultrasound guidance, to
associate additional morphological data with functional identiﬁ-
cation. The combination of these two technologies is inexpensive,
does not involve radiation and is easy to implement.
In addition to the anatomical variants advanced by some
authors to discuss the indication for surgery [14–19], most authors
retain the abnormal contracture of the piriformis muscle, although
sometimes without ﬁnding any speciﬁc risk factor. Thus,
botulinum toxin (shown to decrease muscle hyperactivity) seems
to be the ideal product to decrease this state of contracture
[3,5,12]. The main objective is to inﬂuence the compression of the
sciatic nerve by muscle relaxation. In addition, the effect of the
toxin indirectly generates partial and secondary atrophy of the
piriformis muscle, especially if injections are repeated. We have
demonstrated this process in further work [20].
The toxin has satisfactory muscle-relaxant action on the
piriformis muscle. Changing the volume of the piriformis muscle
and indirectly optimizing the ratio of content to container at the
infra-piriformis foramen remains an attractive therapeutic option.
All patients were monitored and evaluated in terms of muscle
strength on the gluteal lateral rotator muscles, and no deﬁcit was
observed.
The ﬁrst 10 patients we recruited received a cortisone injection.
The beneﬁt was not consistent and never observed beyond day
10. Therefore, we proposed to use botulinum toxin for manage-
ment. The superiority of botulinum toxin was conﬁrmed in various
publications [3,5,21]. Although the effect was sometimes equiva-
lent, a signiﬁcant superiority of corticosteroids associated with an
anesthetic over botulinum toxin has never been reported.
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